Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

A Randomized, Multi-Center, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Prophylactic Emicizumab versus No Prophylaxis in Hemophilia A Patients with Inhibitors

Clinical Trial Details

This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics. 

Study contact by location

Upper East Side - Manhattan

Contact(s)

Ilene Goldberg
(212) 746-3403
igoldber@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1508016468

Status

Open to Enrollment

Age Group

Adult , Pediatric

Disease